PEGylated PLGA nanoparticles for the improved delivery of doxorubicin

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 5, Issue 4, 2009, Pages 410-418

  Park, Jason ^a   Fong, Peter M ^a   Lu, Jing ^b   Russell, Kerry S ^c   Booth, Carmen J ^d   Saltzman, W Mark ^a   Fahmy, Tarek M ^a  

^a Yale University   (United States)

^b Carigent Therapeutics Inc   (United States)

^c Yale Cardiology   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Doxorubicin; Drug delivery; Nanoparticle; PEGylated; PLGA

Indexed keywords

AVIDIN-BIOTIN; B-CELL LYMPHOMA; CARDIOTOXICITY; CONTROLLED RELEASE; COUPLING SYSTEMS; DOXORUBICIN; DRUG DELIVERY NANOPARTICLE; LEFT VENTRICULAR; PATHOLOGICAL CHANGES; PEGYLATED NANOPARTICLE; PLGA NANOPARTICLES; POLY(LACTIC-CO-GLYCOLIC ACID); SURFACE MODIFICATION TECHNIQUES;

ANIMAL CELL CULTURE; ANIMALS; CELL CULTURE; CONTROLLED DRUG DELIVERY; ECHOCARDIOGRAPHY; ENCAPSULATION; ETHYLENE; ETHYLENE GLYCOL; ONCOLOGY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES;

NANOPARTICLES;

AVIDIN; BIOTIN; CREATINE KINASE; DOXORUBICIN; DRUG CARRIER; MACROGOL; NANOPARTICLE; PEGYLATED POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER TRANSPLANTATION; CARDIOMYOPATHY; CARDIOTOXICITY; CONJUGATION; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ECHOCARDIOGRAPHY; ENCAPSULATION; FEMALE; HEART LEFT VENTRICLE; HISTOPATHOLOGY; HYPOTHESIS; LYMPHOMA CELL; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE;

ADSORPTION; ANIMALS; CATTLE; CELL DEATH; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GLYCOLATES; HEART; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SERUM ALBUMIN, BOVINE; SURFACE PROPERTIES; TISSUE DISTRIBUTION; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; MURINAE; MUS;

EID: 68549132581     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.02.002     Document Type: Article

References (24)

1. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70 (2001) 1-20
2. Anderson J.M., and Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28 (1997) 5-24
3. Okada H., and Toguchi H. Biodegradable microspheres in drug-delivery. Crit Rev Ther Drug Carrier Syst 12 (1995) 1-99
4. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., and Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6 (2000) 1949-1957
5. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42 (2003) 463-478
6. Faraasen S., Voros J., Csucs G., Textor M., Merkle H.P., and Walter E. Ligand-specific targeting of microspheres to phagocytes by surface modification with poly(l-lysine)-grafted poly(ethylene glycol) conjugate. Pharm Res 20 (2003) 237-246
7. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surfaces B-Biointerfaces 18 (2000) 301-313
8. Li Y.P., Pei Y.Y., Zhang X.Y., Gu Z.H., Zhou Z.H., Yuan W.F., et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release 71 (2001) 203-211
9. Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 (2004) 3122-3131
10. Allen T.M., and Martin F.J. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 31 (2004) 5-15
11. Biragyn A., and Kwak L.W. Models for lymphoma. In: Coico R. (Ed). Current protocols in immunology (2001), John Wiley and Sons, Inc., Hoboken, NJ 20.6.1-20.6.30
12. Fahmy T.M., Samstein R.M., Harness C.C., and Saltzman W.M. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26 (2005) 5727-5736
13. Myers C.E., McGuire W.P., Liss R.H., Ifrim I., Grotzinger K., and Young R.C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197 (1977) 165-167
14. Kang Y.J., Chen Y., and Epstein P.N. Suppression of cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271 (1996) 12610-12616
15. Teraoka K., Hirano M., Yamaguchi K., and Yamashina A. Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2 (2000) 373-378
16. Jacoby J.J., Kalinowski A., Liu M.G., Zhang S.S.M., Gao Q., Chai G.X., et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A 100 (2003) 12929-12934
17. Davis M.E., Chen Z., and Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7 (2008) 771-782
18. Johansen P.B. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude-mouse. Cancer Chemother Pharmacol 5 (1981) 267-270
19. Bouma J., Beijnen J.H., Bult A., and Underberg W.J.M. Anthracycline antitumour agents. Pharm World Sci 8 (1986) 109-133
20. Allen T.M., Mumbengegwi D.R., and Charrois G.J.R. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 11 (2005) 3567-3573
21. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117 (2006) 78-88
22. Lamprecht A., and Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glyco-protein inhibition. J Control Release 112 (2006) 208-213
23. Soma C.E., Dubernet C., Barratt G., Nemati F., Appol M., Benita S., and Couvreur P. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res 16 (1999) 1710-1716
24. Wong H.L., Bendayan R., Rauth A.M., and Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 116 (2006) 275-284